References
- Almasan A, Ashkenazi A (2003). Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev, 14, 337-48. https://doi.org/10.1016/S1359-6101(03)00029-7
- Amirijavid S, Hashemi M (2015). Detection of anticancer and apoptotic effect of the produced IgYs against the three extracellular domain of human DR5 protein. Iran J Cancer Prev, 8,109-15.
- Amirijavid S, Hashemi M (2014). Anticancer effect of the IgY that produced against a small peptide with 15 amino acids of human DR5 on MCF7 cell line. JPS, 5,1-6.
- Ashkenazi A (2002). Targeting death and decoy receptors of the tumor necrosis factor superfamilly. Nat Rev Cancer, 2, 420-300. https://doi.org/10.1038/nrc821
- Bellail AC, Qi L, Mulligan P, et al (2009). TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials, 4, 34-41. https://doi.org/10.2174/157488709787047530
- Benedict CA, Banks TA, et al. (2003). Death and survivel: viral regulation of TNF signaling pathways.Curr Opin Immunol, 15, 59-65. https://doi.org/10.1016/S0952-7915(02)00018-3
- Bodmer JL, Schneider P, et al (2002). The molecular architecture of the TNF superfam.Trends. Biochem Sci, 27,19-26. https://doi.org/10.1016/S0968-0004(01)01995-8
- Cha SS, Sung BJ, et al. (2000). Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J BiolChem, 275, 31171-7.
- Chaudhary PM, Eby M, et al (1997). Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappa B pathway. Immunity,7,821-30. https://doi.org/10.1016/S1074-7613(00)80400-8
- Heidari MH, Porghasem M, Mirzaei N, et al (2014). The effect of high level natural ionizing radiation on expression of PSA, CA19-9 and CEA tumor markers in blood serum of inhabitants of Ramsar, Iran. J Environ Radioact, 128, 64-7. https://doi.org/10.1016/j.jenvrad.2013.11.001
- Gajewski TF (2007). On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol, 25,1305-7. https://doi.org/10.1200/JCO.2006.09.9804
- Ichikawa K, Liu W, et al (2001). Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med,7, 954-60. https://doi.org/10.1038/91000
- Kelley RF, Totpal K, et al (2005). Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J BiolChem, 280, 2205-12.
- Mahalingam D, Szegezdi E, et al (2009). TRAIL receptor signalling and modulation: Are we on the right TRAIL?. Cancer Treat Rev, 35, 280-8. https://doi.org/10.1016/j.ctrv.2008.11.006
- Mori E, Thomas M, et al (2004). Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ, 11, 203-7. https://doi.org/10.1038/sj.cdd.4401331
- Movafagh A, Hajifathali A, Zamani M (2011). Secondary chromosomal abnormalities of de novo acute myeloid leukemia-a first report from the Middle East. Asian Pac J Cancer Prev, 12, 2991-4.
- Movafagh A, Mirfakhraei R, Mousavi-Jarrahi A (2011). Frequent incidence of double minute chromosomes in cancers, with special up-to-date reference to leukemia. Asian Pac J Cancer Prev, 12, 3453-6.
- Movafagh A, Hajifathali A, Isfahani F, et al (2012). Geographic heterogeneity of cytogenetic characteristics of acute myeloid leukemia in the early detection. Iran J Cancer Prev, 2, 85-89.
- Pan G, Ni J, et al (1997). Anantagonist decoyreceptor and a death domain-containing receptor for TRAIL. Science , 277,815-8. https://doi.org/10.1126/science.277.5327.815
- Pan G, O'Rourke K, et al (1997). The receptor for the cytotoxic ligand Trail. Science , 276,111-3. https://doi.org/10.1126/science.276.5309.111
- Peto R, Boreham J, et al (2000). UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet, 355, 1822-3.
- Reed JC (2006). Drug insight cacner therapy strategis, based on restoration of endogenous cell death mechanism. Nat clin pract oncol, 3, 388-98. https://doi.org/10.1038/ncponc0538
- Schneider P, Thome M, et al (1997). TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity,7, 831-6. https://doi.org/10.1016/S1074-7613(00)80401-X
- Seifi-Alan M, Shamsi R, Ghafouri-Fard S, et al (2014). Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines. Asian Pac J Cancer Prev, 14, 6625-9.
- Shargh SA, Sakizli M, Khalaj V, et al ( 2014) Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol, 31, 250-9. https://doi.org/10.1007/s12032-014-0250-y
- Walczak H, Degli-Esposti MA, et al (1997). Trail R2: a novel apoptosis mediating receptor. EMBO,16, 5386-97. https://doi.org/10.1093/emboj/16.17.5386
- Wei W, Liu Y, et al (2005). Current understanding on the immunological functions of tumor necrosis factor-related apoptosis-inducing ligand. Cell MolImmunol, 2, 265-9.
- Wiley SR, Schooley K, et al (1995). Identification and characterization of a new member of theTNF family that induces apoptosis. Immunity, 3, 673-82. https://doi.org/10.1016/1074-7613(95)90057-8
- Wu GS, Burns TF, et al (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet, 17, 141-3. https://doi.org/10.1038/ng1097-141